Home Stocks and ETFs TARS
Tarsus Pharmaceuticals Inc
52-Week Low10.8001
What does the Tarsus Pharmaceuticals Inc do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
How much money does Tarsus Pharmaceuticals Inc make?
News & Events about Tarsus Pharmaceuticals Inc.
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ...
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of TP-05 in healthy subjects TP-05 designed to be an on-demand, long-acting prophylactic treatment that...
Zolmax
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS Get Rating) CFO Leonard M. Greenstein sold 5,000 shares of the businesss stock in a transaction on Thursday, October 20th. The stock was sold at an average price of $15.92, for a total value of $79,600.00. Following the transaction, the chief ...
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating meibomian gland atrophy in patients with Demodex blepharitis will also be presented IRVINE, Calif., Oct. ...
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermanns expected transition IRVINE, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (...
What is Tarsus Pharmaceuticals Inc share price today?
Can Indians buy Tarsus Pharmaceuticals Inc shares?
How can I buy Tarsus Pharmaceuticals Inc shares from India?
Can Fractional shares of Tarsus Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Tarsus Pharmaceuticals Inc stocks?
What is today's traded volume of Tarsus Pharmaceuticals Inc?
What is today's market capitalisation of Tarsus Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Tarsus Pharmaceuticals Inc?
What percentage is Tarsus Pharmaceuticals Inc down from its 52-Week High?
What percentage is Tarsus Pharmaceuticals Inc up from its 52-Week Low?
Start Investing in TARS
POSEIDA THERAPEUTICS INC
PMV PHARMACEUTICALS INC
FOGHORN THERAPEUTICS INC
BioAtla Inc